Logo

Aventis Extends Spotfire Deal

Jun 19, 2002

NEW YORK, June 19-Aventis has signed a new multi-year deal with Spotfire for expanded use of the database querying and analysis program DecisionSite, the software company said today.

 

Under the terms of this deal, the two will work jointly to adapt Spotfire software for Aventis' drug discovery efforts. The pharmaceutical company also has access to a new module of the software.

 

The deal extends an agreement made last June, whereby Spotfire and IBM are collaborating to combine their information management, infrastructure and biological analysis capabilities for the benefit of Aventis.The pharmaceutical giant is using Spotfire and IBM products for all its research and discovery efforts.

 

For more information, click here.

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.